| Study Number | Completed Clinical Trial Report Summaries |
291 | A Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Effects of Esomeprazole 40 mg bid on the Signs and Symptoms of Chronic Posterior Laryngitis in Patients with Suspected Laryngopharyngeal Reflux |
311 | A Multi-Centered, Phase IV, Post-Marketing, Prospective, Randomized, Double-Blind Study Comparing Esomeprazole Magnesium 40 mg Once Daily versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects with Persistent Symptoms of Gastroesophageal Reflux Disease While on 30 mg Once Daily Lansoprazole Therapy |
314 | A Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Effects of Timing of Dosing in Relation to Food on the Pharmacokinetics of Esomeprazole Magnesium (NEXIUM) in Healthy Subjects |
322 | A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment with Esomeprazole Magnesium (40 mg qd) to Lansoprazole (30 mg qd) for the Healing of Erosive Esophagitis in Patients with Moderate or Severe Erosive Esophagitis |
D9612C00026 | An Open, Single-Centre, Randomized, 6-way Crossover, Dose-Response Comparative Study of Esomeprazole 20, 40 and 80 mg and Pantoprazole 20, 40 and 80 mg regarding 24-hour Intragastric pH following 5 Days Repeated Oral Dose Administration in Patients with Symptoms of Gastroesophageal Reflux Disease. |
D9615C00013 | An Open, Randomized, Two-Way Crossover Study Comparing the Effect of 40 mg Esomeprazole Administered Orally and Intravenously as a 3-minute Injection on Basal and Pentagastrin-Stimulated Acid Output in Patients with Symptoms of Gastroesophageal Reflux Disease (GERD) |
D9615C00014 | An Open, Randomized, Two-Way Crossover Study Comparing the Effect of 20 mg Esomeprazole Administered Orally and Intravenously as a 3-minute Injection on Basal and Pentagastrin-Stimulated Acid Output in Patients with Symptoms of Gastroesophageal Reflux Disease (GERD) |
D9615C00019 | A Randomised, Double-Blind, Placebo Controlled Explorative Study to Investigate the Efficacy and Safety of Esomeprazole in the Prevention of Post Operative Nausea and Vomiting |
D961AC00001 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment with Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients with Heartburn and Sleep Disturbances Associated with Gastroesophageal Reflux Disease (GERD) |
SH-NEG-0008-D9612C09008 | PPI Comparator Study to Compare the Efficacy of Healing and Maintenance treatment with Esomeprazole and Pantoprazole in Subjects with Reflux Oesophagitis – A Multi-Centre, Randomized, Double-Blind Study - EXPO |
SH-NEH-0001-D9612C09991 | A randomised, comparative, double-blind, parallel group, multi-centre Phase IIIa study to eradicate Helicobacter Pylori, heal gastric ulcer and prevent relapse in gastric ulcer subjects with esomeprazole in combination with amoxicillin and clarithromycin |
D9612L00048 (325) | Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates for Once Daily Treatment with Esomeprazole 20 mg and Lansoprazole 15 mg for 6 months in Patients whose EE Has Been Healed |
D9612L00063 | A Randomized, Open-Label, Comparative 3-way Crossover Study of 24-hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in NSAID-using Patients |
D9612L00066 | A Randomized, Open-Label, Comparative, Two-Treatment, Crossover Study of the 24-Hour Intragastric pH Profile After 5 Days of Once Daily Oral Administration of Either Esomeprazole 40 mg or Pantoprazole 40 mg Following Once Daily Infusion of Intravenous Pantoprazole 40 mg for 5 Days in Healthy Volunteer Subjects |
D9612L00056 (315) | A Multicenter, Double-blind, Three-way Crossover Intraesophageal and Intragastric pH Study of Three Esomeprazole Treatment Regimens in Documented Barrett’s Esophagus Patients |
D9612L00057 (316) | A Multicenter, Open-label, Four-way Crossover Study of the Effects of Esomeprazole, Aspirin and Rofecoxib on Prostaglandin (PGE2) Production, Cyclooxygenase-2 Enzyme Activity and PCNA Expression in Patients with Barrett’s Esophagus |
D9612L00085 | A randomised, open, phase IV, parallel group multicentre study to evaluate a change of management in Gastroesophageal Reflux Disease (GERD) patients by treatment with esomeprazole 40 mg or any other Proton Pump Inhibitor (PPI), after initial treatment failure, in ordinary clinical practice during 4 weeks. |
D9612L00106 | A Randomized, Open-Label, Comparative 3-way Crossover Study of 24-hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at
Steady State in Hispanic Patients with Symptomatic GERD |
D9612L00109 | SYMPATHY (Symptom Adapted Therapy)
A randomised, open, parallel-group, multi-national, multi-centre, phase IV study to evaluate the efficacy of three different subject management strategies with and without esomeprazole 20 mg during a 3 months
maintenance phase following an initial 4-weeks acute treatment phase in subjects with symptoms thought to be GERD related |
D9612L00107 | An Open-Label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium® I.V. (esomeprazole sodium) 40 mg BID for up to 72 hours |
D961FC00001 | A Phase I, Open, Randomized, Single-centre, 3-way Crossover Drug-drug Interaction Study of Esomeprazole Capsule 40 mg and Low-dose Acetylsalicylic Acid Tablet 325 mg after 5 days Repeated Oral
Administration in Healthy Male and Female Subjects |
D961FC00001 | A randomised, double-blind, double-dummy, parallel-group, activecontrolled, multicenter study to assess the efficacy and safety of esomeprazole 40 mg q12h i.v. or omeprazole 40 mg q12h iv administration for 5 days in subjects with acute non-variceal upper gastrointestinal bleeding |
D961DL00004 | A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- Controlled Efficacy Study Comparing 4 Weeks of Treatment with Esomeprazole 20 mg qd to Placebo qd for the Resolution of Upper Abdominal Pain in Patients with Symptomatic Gastroesophageal Reflux Disease (sGERD) |
D9612L00011 | A study to assess the effectiveness of maintenance treatment with esomeprazole 20mg od in patients with reflux disease previously maintained with lansoprazole 30mg od - A 3 month, randomised, double blind, double dummy, multicentre study- (30/20 Study). |
D9612L00104 | A study to assess the effectiveness of Esomeprazole 40 mg once daily patients with continuing Gastroesophageal Reflux Disease (GORD) following treatment with a previous full dose Proton Pump Inhibitor An 8 week, open label, multicentre study. (RESPONSE Study) |
D9612L00097 | Use of esomeprazole in postoperative bariatric surgery patients users and non-users of nonsteroidal anti-inflammatory drugs (NSAIDs) |
D9615L00005 | A randomised, double-blind, double dummy, multicentre study to evaluate the efficacy and safety of esomeprazole 40 mg given i.v. or orally o.d. for 1 week to subjects with erosive reflux esophagitis, followed by 3 weeks' open oral treatment with esomeprazole 40 mg o.d. |
D9612C00100 | An Open, Single-centre, Randomised, Six-way crossover, Dose-response Study of Esomeprazole 20, 40 and 80 mg and Lansoprazole 15, 30 and 60 mg Regarding 24-hour Intragastric pH Following Repeated Oral Dose Administration in Healthy Male and Female Subjects |
D9914C00001 | A Randomized Double-Blind Placebo-Controlled Multi-Centre Pilot Study to Assess Symptom Response in Subjects with Pain or Discomfort in the Chest Receiving Oral Treatment with Esomeprazole 40 mg bid for 4 weeks |
D9914C00002 | A single-blind single arm study to validate the Reflux Disease Questionnaire (RDQ) for the diagnosis of reflux disease in primary care in patients treated with esomeprazole 40 mg o.d. |
DC-QBE-0001
| A bioequivalence study with 20 mg H 199/18 comparing a new tablet formulation with a capsule formulation in healthy subjects |
DC-QBE-0002
| A bioequivalence study with 40 mg H 199/18 comparing a new tablet formulation with a capsule formulation in healthy subjects |
DC-QBE-0004 | A comparison study of the pharmacodynamic effect of a 40 mg H199/18 MUPS™ tablet formulation versus a capsule formulation in patients with gastroesophageal reflux symptoms |
DC-QBE-0019 | A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment with Esomeprazole Magnesium (40 mg qd) to Lansoprazole (30 mg qd) for the Healing of Erosive Esophagitis in Patients with Moderate or Severe Erosive Esophagitis |
SH-NEC-0001 | A Single-Blind, Randomised, Parallel-Group, Single-Centre Pharmacokinetic and pH-Monitoring Study of Esomeprazole in Infants up to 24 Months of Age. |
SH-NEC-0002 | An Open Single-centre Study on the Pharmacokinetics and Pharmacodynamics of Esomeprazole After Once Daily Oral Administration for 7 Days in Preterm Infants and Neonates. |
SD-NED-0021 | Supportive Test for Acid-Related Symptoms (STARS I) with esomeprazole and a following 7-week, double-blind, randomized, placebo-controlled treatment period in subjects with upper gastrointestinal symptoms and with normal findings at esophagogastroduodenoscopy |
SD-NED-0022 | Supportive Test for Acid-Related Symptoms (STARS II) with esomeprazole and a following 7-week, double-blind, randomized, placebo controlled treatment period in uninvestigated patients with upper gastrointestinal symptoms |
SD-NEE-0003 | A randomized, double-blind, parallel-group multicentre efficacy and safety phase IIB pilot study of esomeprazole 40 mg twice daily versus placebo twice daily in adult asthmatics treated for 4 months |
SH-NEG-0004 | On demand vs continuous treatment of endoscopy negative subjects with gastroesophageal reflux disease (GERD) with esomeprazole 20 mg once daily over a 6 months long term treatment phase. An open, randomised, multicenter study, NEED |
SH-NEG-0005 | Evaluating the benefit of continuous versus on demand Nexium® therapy: A randomised study on the efficacy of maintenance therapy in gastroesophageal reflux disease patients – (BRILLIANT) |
SH-NEH-0002 | A four-way cross-over multpel-dose open-label pharmacokinetic drug inteaction study with esomeparzole 20 mg b.i.d., metronidazole 500 mg b.i.d., clarithromycin 250 mg b.i.d. and their combination b.i.d. in healthy non-smoking male and female subjects. |
SH-NEN-0001 | Efficacy of esomeprazole 40 mg once daily versus placebo and esomeprazole 20 mg once daily versus placebo in treatment for relief of upper gastrointestinal symptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs |
SH-NEN-0002 | Efficacy of esomeprazole 40 mg once daily versus placebo or esomeprazole 20 mg once daily versus placebo in prevention of upper gastrointestinal symptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs |
SH-NEN-0003 | Efficacy of esomeprazole 40 mg once daily versus placebo and esomeprazole 20 mg once daily versus placebo in treatment for relief of upper gastrointestinal symptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs |
SH-NEN-0004 | Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated with Continuous Use of NSAIDs Including COX-2 Selective NSAIDs |
SH-NEN-0005 | A Comparative Efficacy and Safety Study of NEXIUM® (esomeprazole magnesium) Delayed-Release Capsules (40 mg qd and 20 mg qd) Versus Ranitidine (150 mg bid) for the Healing of NSAID-associated Gastric Ulcers When Daily NSAID Use is Continued |
SH-NEN-0006 | A Comparative Efficacy and Safety Study of NEXIUM® (esomeprazole magnesium) Delayed-Release Capsules (40 mg qd and 20 mg qd) Versus Ranitidine (150 mg bid) for the Healing of NSAID-associated Gastric Ulcers When Daily NSAID Use is Continued |
SH-NEN-0007 | A Comparative Efficacy and Safety Study of NEXIUM® (esomeprazole magnesium) Delayed-Release Capsules (40 mg qd and 20 mg qd) Versus Placebo for the Healing of NSAID-associated Gastric Ulcers When Daily NSAID Use is Discontinued |
SH-NEN-0008 | A Comparative Efficacy and Safety Study of NEXIUM® (esomeprazole magnesium) Delayed-Release Capsules (40 mg qd and 20 mg qd) Versus Placebo for the Healing of NSAID-associated Gastric Ulcers When Daily NSAID Use is Discontinued |
SH-NEN-0013 | A comparative efficacy and safety study of Nexium( (esomeprazole magnesium) delayed-release capsules (40 mg qd and 20 mg qd) versus placebo for the prevention of gastric ulcers associated with daily NSAID use in patients at risk
|
SH-NEN-0014 | A Comparative Efficacy and Safety Study of NEXIUM® (esomeprazole magnesium) Delayed-Release Capsules (40 mg qd and 20 mg qd) Versus Placebo for the Prevention of Gastric Ulcers Associated with Daily NSAID Use in Patients at Risk |
SH-NEP-0006 | A randomised, double-blind, multicentre Phase III study to evaluate safety of esomeprazole 40 mg given intravenously or orally od for 1 week to subjects with erosive reflux oesophagitis, followed by 3 weeks’ open oral treatment with esomeprazole 40 mg od. |
SH-NEP-0011 | An Open, Randomized, Two-Way Crossover Study Comparing the Effect of 40 mg Esomeprazole Administered Orally and Intravenously as a 15 minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Patients with Symptoms of Gastroesophageal Reflux Disease (GERD) |
SH-NEP-0012 | An Open, Randomized, Two-Way Crossover Study Comparing the Effect of 20 mg Esomeprazole Administered Orally and Intravenously as a 15 minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Patients with Symptoms of Gastroesophageal Reflux Disease (GERD) |
SH-QBE-0003 | The aim of the study was to investigate the pharmacokinetics of diazepam and the formation of one of its active metabolites, N-desmethyldiazepam, after a single i.v. dose, during repeated oral administration of H 199/18 or placebo in healthy subjects. |
SH-QBE-0005 | Pharmacokinetics of quinidine with and without co-administration of H 199/18 sodium in healthy volunteers |
SH-QBE-0008 | Comparative study on 20 and 40 mg H 199/18 and 20 mg omeprazole with regard to effect on 24-hour intragastric pH |
SH-QBE-0009 | A dose-finding/efficacy and safety study of H 199/18 vs. omeprazole management of patients with gastroesophageal reflux symptoms without macroscopic esophagitis - A multicenter study |
SH-QBE-0010 | A placebo-controlled study on the efficacy of on demand treatment with two doses of H 199/18 in maintaining control of symptoms in patients with gastroesophageal reflux disease without macroscopic esophagitis - A multicentre study |
SH-QBE-0011 | An efficacy and safety study of H 199/18 40 mg vs. omeprazole in the management of patients with gastroesophageal reflux symptoms without macroscopic esophagitis - A multicentre study |
SH-QBE-0012 | A placebo-controlled study on the efficacy of on demand treatment with H 199/18 40 mg in maintaining control of symptoms in patients with gastroesophageal reflux disease without macroscopic esophagitis - A multicentre study |
SH-QBE-0013 | A multicenter, randomized, double-blind, eight week comparative efficacy and safety study of H 199/18 20 mg, H 199/18 40 mg and omeprazole 20 mg in study subjects with erosive esophagitis |
SH-QBE-0014 | A multicenter, randomized, double-blind, six-month maintenance study to compare the efficacy, safety, and tolerability of H 199/18 40 mg, H 199/18 20 mg, and H 199/18 10 mg with placebo in healed erosive esophagitis subjects. |
SH-QBE-0015 | A multicenter, randomized, double-blind, six-month maintenance study to compare the efficacy, safety and tolerability of H 199/18 40 mg, H 199/18 20 mg, and H 199/18 10 mg with placebo in healed erosive esophagitis subjects |
SH-QBE-0016 | A multicenter, randomized, double-blind, eight week comparative efficacy and safety study of H 199/18 40 mg and omeprazole 20 mg in study subjects with erosive esophagitis |
SH-QBE-0017 | A multicenter, randomized, double-blind, eight week comparative efficacy and safety study of H 199/18 20 mg and omeprazole 20 mg in study subjects with erosive esophagitis |
SH-QBE-0018 | A multicenter, open-label, long-term safety study of H 199/18 40 mg in subjects with healed erosive esophagitis |
SH-QBE-0019 | The effect of omeprazole or H 199/18 on the efficacy of clarithromycin plus amoxicillin for the eradication of H. pylori in duodenal ulcer patients |
| SH-QBE-0020 | The effect of omeprazole or H 199/18 on the efficacy of clarithromycin plus amoxicillin for Helicobacter pylori eradication and duodenal ulcer healing |
SH-QBE-0021 | An efficacy and safety study of H 199/18 20 mg vs. omeprazole in the management of patients with gastroesophageal reflux symptoms without macroscopic esophagitis - A multicentre study |
SH-QBE-0022 | A placebo-controlled study on the efficacy of on demand treatment with H 199/18 20 mg in maintaining control of symptoms in patients with gastroesophageal reflux disease without macroscopic esophagitis – A multicentre study |
SH-QBE-0026 | Pharmacokinetics of H 199/18 and its main metabolites in patients with varying degrees of impaired liver function |
SH-QBE-0032 | An interaction study between H 199/18 and phenytoin in healthy male and female subjects |
SH-QBE-0033 | A bioequivalence study with 20 mg H 199/18 comparing a new tablet formulation with a capsule formulation in healthy subjects |
SH-QBE-0034 | An interaction study between H 199/18, amoxicillin and clarithromycin in healthy male and female subjects |
SH-QBE-0035 | A bioequivalence study with 40 mg H 199/18 comparing a new tablet formulation with a capsule formulation in healthy subjects |
SH-QBE-0036 | An interaction study between H 199/18 and cisapride in healthy male and female subjects |
SH-QBE-0037 | A pharmacokinetic study of H 199/18 in elderly male and female subjects |
SH-QBE-0038 | An interaction study between H 199/18 and warfarin in warfarin-treated patients |
SH-QBE-0040 | An interaction study between H 199/18 b.i.d., amoxicillin b.i.d. and clarithromycin b.i.d. in healthy male and female subjects |
SH-QBE-0041 | A multicenter, randomized, double-blind, safety and efficacy study of H 199/18 with amoxicillin plus clarithromycin compared to H 199/18 with clarithromycin for the eradication of Helicobacter pylori in subjects with active duodenal ulcer or history of duodenal ulcer disease |
SH-QBE-0042 | A multicenter, randomized, double-blind, safety and efficacy study of H 199/18 with clarithromycin compared to H 199/18 for the eradication of Helicobacter pylori in subjects with active duodenal ulcer or history of duodenal ulcer disease. |
SH-QBE-0043 | A multicenter, randomized, double-blind, safety and efficacy study of H 199/18 with amoxicillin plus clarithromycin compared to H 199/18 for the eradication of Helicobacter pylori in subjects with active duodenal ulcer or history of duodenal ulcer disease |
SH-QBE-0044 | A food interaction study regarding pharmacokinetics and effect on intragastric pH following treatment with H 199/18 capsules in healthy male and female subjects |
SH-QBE-0046 | An interaction study betweeen H 199/18 and phenytoin in epileptic patients |
SH-QBE-0050 | A food interaction study regarding effect on intragastric pH following treatment with H 199/18 tablets in healthy male and female subjects |
SH-QBE-0051 | A pharmacodynamic study comparing a 20 mg MUPS tablet with a 20 mg capsule of H 199/18 in patients with symptomatic gastroesophageal reflux disease |
SH-QBE-0052 | A comparative efficacy and safety study off H 199/18 40 mg and omeprazole 20 mg in study subjects with erosive esophagitis |
SH-QBE-0053 | A comparative efficacy and safety study of H 199/18 (20 mg), H 199/18 (40 mg) vs. placebo in study subjects with symptomatic GERD |
SH-QBE-0054 | A comparative efficacy and safety study of H 199/18 (20 mg), H 199/18 (40 mg) vs. placebo in study subjects with symptomatic GERD |
SH-QBE-0055 | A bioequivalence study comparing a H 199/18 market capsule, 40 mg, with the H 199/18 phase III capsule, 40 mg following single and repeated administration under fasting conditions in healthy male and female subjects |
SH-QBE-0056 | A bioequivalence study comparing a H 199/18 market capsule, 40 mg, with the H 199/18 phase III capsule, 40 mg following single dose administration under fed conditions in healthy male and female subjects |
SH-QBE-0057 | To investigate if the market capsule and the phase III capsule of 20 mg H 199/18 are bioequivalent following single dose administration under fasting conditions. |
SH-QBE-0058 | A comparative study on 40 mg H 199/18 and 40 mg pantoprazole with regard to effect on 24-hour intragastric pH in patients with symptomatic gastroesophageal reflux disease |
SH-QBE-0059 | A comparative study on 40 mg H 199/18 and 30 mg lansoprazole with regard to effect on 24-hour intragastric pH in healthy subjects |
SH-QBE-0060 | A comparative study on 40 mg H 199/18 and 40 mg omeprazole with regard to effect on 24-hour intragastric pH in healthy subjects |
SH-QBE-0066 | A comparative study on 40 mg H 199/18 and 40 mg omeprazole with regard to effect on 24-hour intragastric pH in patients with symptomatic gastroesophageal reflux disease |
SH-QBE-0067 | Maintenance treatment of patients with healed reflux esophagitis, comparing remission rates during 6 months with esomeprazole 20 mg q.d. and lansoprazole 15 mg q.d. - A randomised, double-blind multi-centre study - METROPOLE |
SH-QBE-0068 | A randomized, single-center, open-label, two-period cross-over, pharmacokinetic study, to evaluate the bioequivalence of a single 40 mg H 199/18 dose administered as an intact capsule and as an open capsule in healthy male and female volunteers. |
SH-QBE-0069 | Control of histomorphological changes associated with gastro-oesophageal reflux disease: esomeprazole versus ranitidine – CHEER |
SH-QBE-0083 | A Comparative Efficy Studie of Esomeprazole Magnesium (40 mg qd) and Lansoprazole (30 mg qd) in Patients with Erosive Esophagitis - EAZEE |
SH-QBE-0096 | A randomized, open-label, 2-period, crossover pharmacokinetic study to evaluate, after single and multiple doses, whether esomeprazole magnesium (Nexium™) 40 mg opened capsule in water, administered through a nasogastric tube, is bioequivalent to an intact 40 mg capsule, administered orally, in healthy subjects |
SH-QBE-0091 | A single-centre, open, 2-way crossover, comparative study of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily regarding 24-hour intragastric pH following single and repeated oral administration in patients with symptoms of GERD |
SH-QBE-0092 | A Single-centre, Open, Two-way Cross-over, Comparative Study of Esomeprazole 20 mg Once Daily and Rabeprazole 10 mg Once Daily Regarding 24-hour Intragastric pH Following Single and Repeated Oral Administration in Healthy Male and Female Subjects |
SH-QBE-0099 | A single-centre, open, 2-way crossover, comparative study of esomeprazole 20 mg and pantoprazole 20 mg once daily regarding 24-hour intragastric pH following single and repeated oral administration in healthy male and female subjects |
SRP-GB-GERD-2006/01 | An epidemiological, observational study to describe symptom control and impact on daily life of GERD in patients with erosive gastroesophageal reflux disease |
25N54 | To assess the diagnostic accuracy of the proton pump inhibitor test in a primary care population as well as its additional value over reflux history, using the symptom association probability outcome during 24-h oesophageal pH recording as reference test for gastro-oesophageal reflux disease. |
N13 | SYNCHRONISE: Esomeprazole 20 mg once daily for relief of upper gastrointestinal SYmptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs in DutcH general practice: the influence of Risk-factors fOr NSAID associated GI damage on symptom responSE. |